Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTELLIGENT BIO SOLUTIONS INC.INBS · Entity 8088 | Chief Executive Officer | March 18, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTELLIGENT BIO SOLUTIONS INC.
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,540 |
Last balance in matching sequence
After 2026-03-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-03-18 · Grant · Acquired 9,150 · Balance 13,190 F2: On March 18, 2026, the Issuer granted the reporting person 9,150 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan ("2019 Plan"). The awarded shares are subject to time-based vesting after 48 months and are subject to forfeiture until vested. F1: On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis. Row 2 · 2026-03-18 · Grant · Acquired 21,350 · Balance 34,540 F3: On March 18, 2026, the Issuer granted the reporting person 21,350 restricted shares of Common Stock under the 2019 Plan. The awarded shares are subject to joint performance-based and time-based vesting requirements and are subject to forfeiture until vested. F1: On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.
F2: On March 18, 2026, the Issuer granted the reporting person 9,150 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan ("2019 Plan"). The awarded shares are subject to time-based vesting after 48 months and are subject to forfeiture until vested.
F3: On March 18, 2026, the Issuer granted the reporting person 21,350 restricted shares of Common Stock under the 2019 Plan. The awarded shares are subject to joint performance-based and time-based vesting requirements and are subject to forfeiture until vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 20, 2026 21:00 UTC | INTELLIGENT BIO SOLUTIONS INC. INBS · Entity 8088 | GrantCommon Stock | 21,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-011913 · ownership.xml · nonDerivative · entry 2 Simeonidis Harry · CIK 0001831767 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,540 F3 · shares: On March 18, 2026, the Issuer granted the reporting person 21,350 restricted shares of Common Stock under the 2019 Plan. The awarded shares are subject to joint performance-based and time-based vesting requirements and are subject to forfeiture until vested. F1 · balance_after: On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 21:00 UTC | INTELLIGENT BIO SOLUTIONS INC. INBS · Entity 8088 | GrantCommon Stock | 9,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-011913 · ownership.xml · nonDerivative · entry 1 Simeonidis Harry · CIK 0001831767 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,190 F2 · shares: On March 18, 2026, the Issuer granted the reporting person 9,150 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan ("2019 Plan"). The awarded shares are subject to time-based vesting after 48 months and are subject to forfeiture until vested. F1 · balance_after: On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 21:00 UTC | INTELLIGENT BIO SOLUTIONS INC. INBS · Entity 8088 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-038576 · ownership.xml · nonDerivative · entry 1 Simeonidis Harry · CIK 0001831767 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,408 F1 · shares: On September 25, 2024, the Issuer granted the reporting person 40,000 shares of the Issuer's common stock pursuant under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. F2 · balance_after: The number of reported securities has been adjusted to (i) reflect a 1-for-12 reverse stock split effected on January 26, 2024, and (ii) correct a clerical error that had previously caused the reporting person's holding to be underreported by 59 shares. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 17:21 UTC | INTELLIGENT BIO SOLUTIONS INC. INBS · Entity 8088 | PurchaseCommon Stock, par value $0.01 per share | 50 | $1.85 | $92.50 |
DisclosureSEC source: 0001493152-23-031612 · ownership.xml · nonDerivative · entry 2 Simeonidis Harry · CIK 0001831767 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,180 F1 · balance_after: On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 17:21 UTC | INTELLIGENT BIO SOLUTIONS INC. INBS · Entity 8088 | PurchaseCommon Stock, par value $0.01 per share | 100 | $1.92 | $192.00 |
DisclosureSEC source: 0001493152-23-031612 · ownership.xml · nonDerivative · entry 1 Simeonidis Harry · CIK 0001831767 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,130 F1 · balance_after: On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 10:07 UTC | INTELLIGENT BIO SOLUTIONS INC. GBS · Entity 8088 | GrantCommon Stock, par value $0.01 per share | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-028196 · ownership.xml · nonDerivative · entry 1 Simeonidis Harry · CIK 0001831767 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,600 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.